Immunogen shares are trading higher on continued momentum after the FDA advised the company that a new single-arm study in ovarian cancer could support accelerated approval for Mirvetuximab Soravtansine. Based on FDA feedback, the company will initiated a new pivotal trial.

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!